MetaCap

Perspective Therapeutics Inc. (CATX)

NYSE: CATXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.7538-0.0302 (-3.85%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CATX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$91.03M
EPS (TTM)
-$1.25
52-week range
0.73 – 6.16
Day range
0.7407 – 0.79
Volume / Avg
1.39M / 2.70M
Beta
—

52-week range

$0.73$6.16

CATX stock today

On Nov 20, CATX ended the session at $0.7538, shedding $0.0302 (3.85%), versus the S&P 500's 3.70% decline. At this level, CATX sits near the bottom of its 52-week range of $0.73 to $6.16: 87.8% below the high, set on Jan 29, 2026 and 3.3% above the low. CATX is down 72.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 63.9%.

Perspective Therapeutics has posted a net loss over the last twelve months (EPS of -$1.25), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Perspective Therapeutics

Company profile

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Johan M. Spoor
Headquarters
Seattle, WA
Employees
163

Financial highlights

Full financials

Perspective Therapeutics reported a net loss of $103.1 million, compared with a loss of $79.3 million a year earlier. Diluted earnings per share came in at -$1.40.

Perspective Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2022
Revenue——$1.43M$0$10.79M
Growth———-100.00%+7.38%
Net income$-103.12M$-79.28M$-46.51M$-10.76M$-7.27M
EPS (diluted)$-1.40$-1.23$-1.74——

Analyst forecast

Forecast

Consensus (16 analysts)

strong_buy

Avg. price target

$9.71+1188.14%

  • Strong buy 1
  • Buy 13
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $15.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.27 vs $-0.24
Surprise
-12.50%

CATX news

All CATX news

Perspective Therapeutics peers

Health Care sector
CATX peer companies
CompanyPrice% ChgMarket capCompare
NTHINeOnc Technologies Holdings Inc.3.15-9.48%$90.88Mvs CATX
CLLSCellectis S.A. ADR0.9209-7.89%$92.76Mvs CATX
DERMJourney Medical Corporation3.30-7.04%$93.16Mvs CATX
CPIXCumberland Pharmaceuticals Inc.5.84-7.30%$87.57Mvs CATX
RTSNRetension Pharmaceuticals Inc.10.51-19.22%$87.57Mvs CATX
EQEquillium Inc.1.06-5.36%$87.26Mvs CATX
UPBUpstream Bio Inc.1.59-20.50%$87.15Mvs CATX
NRXPNRX Pharmaceuticals Inc.2.15-15.69%$95.31Mvs CATX

Indexes, lists and sector

Perspective Therapeutics stock FAQ

What is Perspective Therapeutics's stock price today?

CATX last traded at $0.7538 as of Nov 20, 4:00 PM EST, down 3.85% on the day. Prices are delayed at least 15 minutes.

Does Perspective Therapeutics pay a dividend?

No. Perspective Therapeutics does not currently pay a regular cash dividend.

Who is Perspective Therapeutics's CEO?

Mr. Johan M. Spoor is the chief executive officer of Perspective Therapeutics Inc., which has about 163 employees.

Has CATX ever split its stock?

Yes. The most recent CATX stock split was a 1-for-10 split on Jun 17, 2024.

What is the CATX 52-week high?

The 52-week high for CATX is $6.16 and the 52-week low is $0.73. The stock is currently 87.8% below its high.

Compare CATX